Latest Investor Relations News

Tasman Resources has clarified the reasons behind its recent share price jump, linking it to new drilling funding and a rise in its Eden Innovations investment value.

Aguia Resources Limited’s AGRO securities have been suspended from trading by ASX Compliance, pending regulatory compliance. The move raises questions about the company’s current standing and next steps.

ASF Group Limited has voluntarily suspended trading of its securities on the ASX pending a response to regulatory queries, signaling heightened scrutiny and market uncertainty.

Black Rock Mining has successfully raised A$4 million through an oversubscribed Share Purchase Plan, doubling its initial target and fueling progress at its Tanzanian Mahenge Graphite Project.

Actinogen Medical has fast-tracked enrolment in its pivotal Alzheimer’s trial, secured a clear FDA regulatory path, and strengthened its financial position with funding extending its runway to mid-2026.

Australian Clinical Labs has announced a 12-month on-market share buy-back program targeting up to 10% of its shares, aiming to enhance shareholder returns without compromising its financial strength.

Alcoa Corporation has announced a quarterly dividend of USD 0.10 per CDI, payable on 21 November 2025, with multiple currency payment options and a 30% withholding tax for non-residents.

Heartland Group Holdings reported a solid first quarter for FY2026, with improved profitability, stable costs, and accelerated realisation of non-strategic assets surpassing expectations.

Codan Limited reported a strong FY25 with significant revenue and profit growth, bolstered by a key U.S. acquisition and a robust outlook for FY26 driven by defense spending and gold market strength.

Australian Vanadium Limited is seeking shareholder approval for a 25 – 1 share consolidation aimed at streamlining its capital structure and enhancing investor appeal without altering shareholder value.

EMVision Medical Devices has closed its $2 million Share Purchase Plan ahead of schedule due to strong investor demand, signaling robust market interest in its neurodiagnostic technology.

Imagion Biosystems has made significant strides toward filing an IND application for its MagSense® HER2 breast cancer imaging agent, supported by positive FDA feedback and a recent $3.5 million capital raise to fund upcoming clinical trials.